Nikko Asset Management Americas’s Vertex Pharmaceuticals VRTX Stock Holding History

Nikko Asset Management Americas’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$958K	Sell	1,930 -185	-9%	-$82K	0.01%	164
2026 Q1	$944K	Sell	2,115 -4,199	-67%	-$1.96M	0.01%	160
2025 Q4	$2.86M	Sell	6,314 -588	-9%	-$253K	0.03%	124
2025 Q3	$2.7M	Buy	6,902 +375	+6%	+$157K	0.03%	126
2025 Q2	$2.9M	Sell	6,527 -145	-2%	-$66.8K	0.03%	124
2025 Q1	$3.23M	Sell	6,672 -707	-10%	-$329K	0.04%	115
2024 Q4	$2.97M	Sell	7,379 -1,092	-13%	-$506K	0.03%	114
2024 Q3	$3.94M	Sell	8,471 -3,349	-28%	-$1.61M	0.04%	113
2024 Q2	$5.54M	Sell	11,820 -3,212	-21%	-$1.39M	0.06%	98
2024 Q1	$6.28M	Sell	15,032 -2,507	-14%	-$1.06M	0.06%	101
2023 Q4	$7.14M	Sell	17,539 -1,233	-7%	-$455K	0.07%	95
2023 Q3	$6.53M	Sell	18,772 -143	-0.8%	-$50K	0.08%	103
2023 Q2	$6.65M	Buy	18,915 +651	+4%	+$219K	0.07%	102
2023 Q1	$5.64M	Sell	18,264 -1,389	-7%	-$417K	0.07%	103
2022 Q4	$5.67M	Sell	19,653 -4,951	-20%	-$1.51M	0.08%	109
2022 Q3	$7.08M	Sell	24,604 -24,981	-50%	-$7.19M	0.09%	100
2022 Q2	$13.6M	Sell	49,585 -31,950	-39%	-$8.55M	0.17%	77
2022 Q1	$21.4M	Sell	81,535 -32,454	-28%	-$7.7M	0.16%	80
2021 Q4	$24.9M	Sell	113,989 -13,207	-10%	-$2.57M	0.13%	88
2021 Q3	$23.1M	Buy	127,196 +19,115	+18%	+$3.73M	0.1%	92
2021 Q2	$21.7M	Sell	108,081 -15,166	-12%	-$3.17M	0.08%	98
2021 Q1	$26.5M	Buy	123,247 +33,798	+38%	+$7.42M	0.13%	97
2020 Q4	$21.1M	Buy	89,449 +5,457	+6%	+$1.25M	0.12%	100
2020 Q3	$22.5M	Buy	83,992 +21,429	+34%	+$5.91M	0.2%	76
2020 Q2	$17.7M	Sell	62,563 -47,860	-43%	-$13M	0.23%	66
2020 Q1	$26.3M	Sell	110,423 -12,467	-10%	-$2.86M	0.49%	57
2019 Q4	$26.9M	Sell	122,890 -3,264	-3%	-$661K	0.42%	62
2019 Q3	$21.4M	Buy	126,154 +20,594	+20%	+$3.64M	0.38%	61
2019 Q2	$19.4M	Buy	105,560 +62,110	+143%	+$10.9M	0.38%	60
2019 Q1	$7.99M	Buy	+43,450	New	+$8.03M	0.21%	78

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nikko Asset Management Americas's VRTX Position: Q2 2026 in Review

Nikko Asset Management Americas reduced its Vertex Pharmaceuticals (VRTX) stake by 8.7% in Q2 2026, selling an estimated $82K and leaving 1,930 shares worth $958K. The position accounts for 0.01% of the portfolio, ranked #164.

Nikko Asset Management Americas first reported a position in VRTX in Q1 2019 and has held it in 30 quarters since. The position peaked at $26.9M in Q4 2019. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Nikko Asset Management Americas held 1,930 shares of Vertex Pharmaceuticals worth $958K as of Q2 2026.
Nikko Asset Management Americas sold 185 Vertex Pharmaceuticals shares in Q2 2026, an estimated $82K.
Vertex Pharmaceuticals made up 0.01% of Nikko Asset Management Americas's portfolio in Q2 2026, its #164 holding.
Nikko Asset Management Americas first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
Nikko Asset Management Americas's Vertex Pharmaceuticals position peaked at $26.9M in Q4 2019.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.